Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.61 |
| ▸ | MMP13 | P45452 | 7/20 | 0.61 |
| ▸ | MMP1 | P03956 | 4/20 | 0.61 |
| ▸ | MMP3 | P08254 | 3/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 12/20 | 0.55 |
| ▸ | MMP7 | P09237 | 2/20 | 0.55 |
| ▸ | MMP8 | P22894 | 3/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28042871 | 1.00 | MMP2 (0.61) | MMP2MMP13MMP1MMP3SLC1A3 | |
| SCHEMBL2219245 | 0.86 | MMP2 (0.56) | MMP2MMP13MMP1MMP3SLC1A3 | |
| SCHEMBL7375346 | 0.86 | SLC1A3 (0.60) | MMP2MMP13MMP1MMP3SLC1A3 | |
| SCHEMBL1734648 | 0.85 | MMP2 (0.60) | MMP2MMP13MMP1MMP3SLC1A3 | |
| SCHEMBL1734649 | 0.85 | MMP2 (0.60) | MMP2MMP13MMP1MMP3SLC1A3 | |
| SCHEMBL1734647 | 0.85 | MMP2 (0.60) | MMP2MMP13MMP1MMP3SLC1A3 | |
| SCHEMBL8839423 | 0.84 | MMP2 (0.64) | MMP2MMP13MMP1MMP3SLC1A3 | |
| SCHEMBL5193396 | 0.84 | TDP1 (0.64) | MMP2MMP13MMP1MMP3SLC1A3 | |
| SCHEMBL1734695 | 0.84 | TDP1 (0.64) | MMP2MMP13MMP1MMP3SLC1A3 | |
| SCHEMBL35211007 | 0.84 | TDP1 (0.64) | MMP2MMP13MMP1MMP3SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105143188-B | Novel sulfonamide TRPA1 receptor antagonists | 阿里奥制药有限公司 | 2017-11-28 | — | — | CN | disclosed |
| US-9409864-B2 | Sulfonamide TRPA1 receptor antagonists | ARIO PHARMA LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160024009-A1 | Novel Sulfonamide TRPA1 Receptor Antagonists | ARIO PHARMA LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| EP-2964615-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | Ario Pharma Limited (GB) | 2016-01-13 | — | — | EP | disclosed |
| CN-105143188-A | Novel sulfonamide trpa1 receptor antagonists | PHARMESTE S R L IN LIQUIDATION | 2015-12-09 | — | — | CN | disclosed |
| WO-2014135617-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | PHARMESTE S.R.L. IN LIQUIDATION (IT) | 2014-09-12 | — | — | WO | disclosed |
| EP-2774919-A1 | Novel sulfonamide TRPA1 receptor antagonists | PHARMESTE S.R.L. IN LIQUIDAZIONE (IT) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024009-A1 | Novel Sulfonamide TRPA1 Receptor Antagonists | TRPA1, TRPV1, TRPV2 | MMP2 3797/4885MMP13 4270/4885MMP1 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.